We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
54 hedge funds and large institutions have $46.6M invested in Crescent Biopharma in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
19% more call options, than puts
Call options by funds: $721K | Put options by funds: $607K
13% more funds holding
Funds holding: 48 → 54 (+6)
0.05% more ownership
Funds ownership: 0.52% → 0.58% (+0.05%)
44% less capital invested
Capital invested by funds: $83.1M → $46.6M (-$36.5M)
Holders
54
Holders Change
+6
Holders Change %
+12.5%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
13
Reduced
10
Closed
13
Calls
$721K
Puts
$607K
Net Calls
+$114K
Net Calls Change
-$924K
Top Buyers
| 1 |
AG
Artal Group
Luxembourg
|
+$19.3M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$6.75M |
| 3 |
Axa
Paris,
France
|
+$3.62M |
| 4 |
Goldman Sachs
New York
|
+$1.88M |
| 5 |
Two Sigma Advisers
New York
|
+$906K |
Top Sellers
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$9.46M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.22M |
| 3 |
Millennium Management
New York
|
-$975K |
| 4 |
First Manhattan
New York
|
-$952K |
| 5 |
EP
Eversept Partners
New York
|
-$305K |
